CTOs on the Move

Promab Biotechnologies

www.promab.com

 
Promab Biotechnologies is a Albany, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.promab.com
  • 715 Johnson St
    Albany, CA USA 94706
  • Phone: 510.860.4615

Executives

Name Title Contact Details

Similar Companies

Avalon Pharmaceuticals

Avalon Pharmaceuticals , Inc. is a Germantown, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SwanBio Therapeutics

With offices in Philadephia and Boston, SwanBio Therapeutics is developing leading-edge therapies to deliver dramatic clinical efficacy for the treatment of neurological diseases. We are driven by an unrelenting passion to solve difficult challenges, and a belief that meaningful discovery is borne of curiosity, collaboration, and compassion. Founded by proven industry leaders with a commitment to positively impacting the lives of people with neurological diseases, SwanBio merges clinical, scientific and drug commercialization expertise.

Sonoma Biotherapeutics

Sonoma Biotherapeutics is inventing the future of living therapies for autoimmune disease — safe, effective treatments as unique as each individual patient. Regulatory T cell therapies that harness a patient`s own immune cells, powerful next generation gene editing techniques and advanced manufacturing and quality assurance processes. Sonoma`s mission is to create a best-in-class regulatory T cell therapy that delivers long-lasting, highly efficacious treatments leading to cures across a spectrum of autoimmune and degenerative diseases.

Roche NimbleGen

Roche NimbleGen is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sensei Biotherapeutics

Driven by world class scientists and an entrepreneurial culture focused on rigorous science, innovative treatments, and data-driven decision making, we discover and develop medicines that have the potential to alter the treatment landscape and contribute value to patients and society. The company has developed a unique drug discovery approach, ImmunoPhage™️, that generates powerful and specific immune responses. Its most advanced program, SNS-301, is currently enrolling patients in Phase 1/2 clinical trials.